Collegium Pharmaceutical, Inc. reported financial results for Q4 2020, with Xtampza ER revenues increasing by 12% and net income reaching $7.0 million, a significant turnaround from the previous year's net loss. The company's performance was driven by its differentiated pain portfolio and the acquisition of the Nucynta franchise.
Xtampza ER net product revenues increased by 12% to $30.8 million.
Nucynta franchise net product revenues were $45.5 million.
Net income was $7.0 million, or $0.20 earnings per share.
The company secured new exclusive ER oxycodone formulary wins for Xtampza ER.
The Company reiterates its full-year 2021 financial guidance, initially provided on January 6, 2021. Collegium is not providing forward-looking guidance for its full-year 2021 U.S. GAAP net income (loss) or a quantitative reconciliation of forward-looking adjusted EBITDA.
Analyze how earnings announcements historically affect stock price performance